Radiotherapy approaches to pituitary tumors
|
|
- Mervin Flynn
- 5 years ago
- Views:
Transcription
1 Disclosures No relevant disclosures Radiotherapy approaches to pituitary tumors Pituitary Disorders: Advances in Diagnosis and Management Steve Braunstein, MD, PhD UCSF Department of Radiation Oncology CNS and Pediatric Service 2 Outline Classification Overview of radiotherapy in management of pituitary tumors Indication/decision algorithm Conventional/fractionated external beam radiotherapy (EBRT) Stereotactic radiosurgery (SRS) Fractionated stereotactic radiotherapy (FSRT/SBRT) Disease outcomes Follow up protocol Toxicity Future directions Tumors of the pituitary Tumor type Transcription factors Hormones, others The Pit-1 family Somatotroph adenoma Densely granulated somatotroph adenoma Pit-1 GH, a-subunit Sparsely granulated somatotroph adenoma Pit-1 GH, keratin whorls (fibrous bodies) Mammosomatotroph/mixed adenoma Pit-1, ER GH, PRL, a-subunit Lactotroph adenoma Sparsely granulated lactotroph adenoma Pit-1, ER,?GH-repressor PRL, Golgi pattern Densely granulated lactotroph adenoma Pit-1, ER,?GH-repressor PRL diffuse cytoplasmic Acidophil stem cell adenoma Pit-1, ER PRL, (GH), keratin whorls (fibrous bodies) Thyrotroph adenoma Pit-1, TEF, GATA-2 b-tsh, a-subunit Plurihormonal adenoma Pit-1, ER, TEF, GATA-2 GH, PRL, b-tsh, a-subunit ACTH family Corticotroph adenoma Tpit ACTH, keratins Gonadotropin family Gonadotroph adenoma SF-1, ER, GATA-2 b-fsh, b-lh, a-subunit Unclassified adenoma Hormone-negative/ null cell adenoma None None Unusual plurihormonal adenoma?multiple Multiple Al-Shraim et al. Acta Neuropath
2 Classification Post surgical outcomes Tumors of the pituitary Pituitary adenoma Microadenoma (<1cm) Macroadenoma ( 1cm) Overall local control is 50-80% following resection Recurrence Risk for non-functional tumors: Post-op MRI 5 yr 10 yr GTR 10-20% 30% STR 25-40% >50% Functional Non-functional Pituitary carcinoma Metastases (breast and lung) Cortet-Rudelli et al. Annales d Endocrinologie Radiotherapy indications Radiotherapy approach Surgical local control 50-80% Medically inoperable (panhypopituitarism) Subtotal resection (persistent hypersecretion) Large tumor with extrasellar extension Recurrence Pituitary carcinoma (high mitotic index, invasive features) Pre-treatment workup Complete endocrine evaluation Visual field testing Cessation of suppressive medications Non-randomized data 7 8
3 Radiotherapy approach Fractionated external beam radiotherapy Effect of endocrine suppression Conventionally/classically fractionated (LINAC-based) Nonfunctioning: Gy Functioning: Gy HS No-HS Sheehan et al. JNS Fractionated external beam radiotherapy Fractionated external beam radiotherapy Conventionally/classically fractionated (LINAC-based) 45 Gy McCoullough WM IJROBP 1991, 95% LC Zeirhut et al. IJROBP 1995 Preferred when large pituitary adenomas and/or when lesion is < 2mm from optic chiasm 11 12
4 Stereotactic radiosurgery Stereotactic radiosurgery Single session radiosurgery (Gamma knife, Cyberknife, LINAC) Nonfunctioning: Gy Functioning: Gy Single session radiosurgery (Gamma knife, Cyberknife, LINAC) Preferred to decrease dose to hypothalamus and cortical brain Fractionated stereotactic radiotherapy Outcomes Multisession radiosurgery (Gamma knife, Cyberknife, LINAC) Nonfunctioning: Gy in 5 fractions Functioning: Gy in 5 fractions Preferred when pituitary lesion is > 3cm and/or when lesion is < 2mm from optic chiasm Tumor type Tteatment protocol Disease free survival 10 yr Non-functioning Surgery obs vs RT 90% RT alone 80% GH-secreting Surgery obs vs RT 70-80% RT alone 60-70% Prolactin secreting Obs vs MM vs Sg vs RT 80-90% ACTH-secreting Surgery obs vs RT 50-60% (more rapid) RT alone 50-60% TSH-sectreing Surgery RT 40-50% 15 16
5 Outcomes Outcomes Functional control ACTH normalizes < 1yr Prolactin > 1yr Growth hormone > 1yr (50% at 2 yr, 70% at 10 yr) Overall survival No difference in OS among: Surgery Surgery + RT RT alone Choose therapy based on minimizing side effects Follow up Outcomes Delayed response and toxicity Pituitary function MRI 6 and 12 months, then annually Endocrine evaluation every 6-12 months Formal visual field testing annually Xu et al. Neurosurgery
6 Outcomes Visual function EBRT: Gy SRS: 8 Gy Total Dose (Gy) 70 Applicability of models to predict RION from conventional to SRS fractionations Models and literature indicate 60 Model: LQ extrapolation from 1.8 Gy/fx, 59.4 Gy with α/β=3.3 better tolerance at lower dose per fraction. Model: LQ extrapolation from 1.8 Gy/fx, 59.4 Gy with α/β=1.6 Model: Iso Neuret(NSD) = 60 Gy, 1.8 Gy/fx 50 Model: Iso Optic RET = 8.9 Gy Literature Findings: > 10% Incidence RION 40 Literature Findings: 1-9% Incidence RION Literature Findings: No Incidence RION 30 Majority of published data pre-date planning and 20 treatment delivery technology that allows for steep dose gradients in or near optic 10 structures. Effect on partial volume tolerance needs Lack of published data in further exploration. hypo-fractionation region Only a few detailed publications in SRS region Dose per Fraction (Gy) Mayo et al. IJROBP 2010 Outcomes/Toxicity Secondary Malignancy Pendulum treatment Two opposed lateral fields Three fields Total Number of patients Median age/years at radiotherapy (range) 54 (24 75) 55 (18 79) 62 (16 82) 56 (16 82) Number of person-years at risk Number of second primary tumours within area of radiotherapy Total number of second primary tumours Number of tumours/10 3 person-years at risk Norberg et al. Clin Endocrinology Outcomes/Toxicity Pituitary carcinoma Secondary Malignancy Type of tumour Sex/age (in years) at radiotherapy for pituitary adenoma Years between radiotherapy and the diagnosis of a second primary tumour Number of fields used and radiation dose received (in Gy) Glioma (astrocytoma grade III) Male/55 7 Two opposed lateral fields, 40 Meningioma Male/46 9 Two opposed lateral fields, 45 Meningioma Male/54 First treatment 24 First treatment: pendulum, 41 Second treatment 1 Second treatment: two opposed lateral fields, 31 Cancer in the parotid gland Female/73 8 Two opposed lateral fields, 42 Squamous cell carcinoma in the external ear Male/51 9 Two opposed lateral fields, 42 Norberg et al. Clin Endocrinology
7 Pituitary carcinoma Future directions Proton Heavy particle Adaptive hybrid radiosurgery LGKS Molecular prognostic markers/indices Heaney J Clin Endocrinol Metab Future directions Molecular Prognostic indices Ki-67, p53, MI Diagnostic Parameters for APAs/TPAs Cut-off Sensitivity Specitifity Youden-Index Accuracy in % AUC 95 % CI of AUC OR 95 % CI of OR Ki-67 pos. nuclei in % [0.96; 1.0] 5.2 [3.43; 7.83] <0.001 P53 pos. nuclei in % [0.90; 0.97] 3.1 [2.31; 4.04] <0.001 Mitotic Index in 10 HPF [0.84; 0.93] 2.1 [1.70; 2.57] <0.001 Invasiveness Yes [3.66; 18.42] <0.001 The proposed threshold values for Ki-67, p53, number of mitotic figures in 10 HPF (high power fields) and the status of invasive tumor growth, to distinguish APA and TPA are shown with their respective statistical values OR odds ratio, AUC area under curve, CI confidence interval P-value Miermeister et al. Acta Neuropathologica Comm Presentation Title and/or Sub Brand Name Here
The Pathology of Pituitary Adenomas. I have nothing to disclose 10/13/2016. Pituitary Disorders: Advances in Diagnosis and Management
The Pathology of Pituitary Adenomas Pituitary Disorders: Advances in Diagnosis and Management October 22, 2016 I have nothing to disclose Melike Pekmezci, MD University of California San Francisco Neuropathology
More information3/22/2017. Disclosure of Relevant Financial Relationships. Disclosure of Relevant Financial Relationships
Ki67 in Pituitary Tumors: What Information Could We Obtain? Robert Y. Osamura, MD International University of Health and Welfare Ki67 in Pituitary Tumors: What Information Could We Obtain? Robert Y. Osamura,
More informationRadioterapia degli adenomi ipofisari
Radioterapia degli adenomi ipofisari G Minniti Radiation Oncology, Sant Andrea Hospital, University of Rome Sapienza, and IRCCS Neuromed, Pozzilli (IS) Roma 6-9 Novembre 14 ! Outline " Radiation techniques
More informationDiseases of pituitary gland
Diseases of pituitary gland A brief introduction Anterior lobe = adenohypophysis Posterior lobe = neurohypophysis The production of most pituitary hormones is controlled in large part by positively and
More informationSomatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234)
Somatotroph Pituitary Adenomas (Acromegaly) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland. In patients
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationImaging pituitary gland tumors
November 2005 Imaging pituitary gland tumors Neel Varshney,, Harvard Medical School Year IV Two categories of presenting signs of a pituitary mass Functional tumors present with symptoms due to excess
More informationSee the latest estimates for new cases of pituitary tumors in the US and what research is currently being done.
About Pituitary Tumors Overview and Types If you have been diagnosed with a pituitary tumor or worried about it, you likely have a lot of questions. Learning some basics is a good place to start. What
More informationAAPM WGSBRT NTCP Optic Apparatus (chiasm and nerve)
AAPM WGSBRT NTCP Optic Apparatus (chiasm and nerve) Michael T. Milano, MD PhD Department of Radiation Oncology University of Rochester, Rochester, NY 07/16/15 AAPM WGSBRT Optic Apparatus NTCP Issam El
More informationImpact of Gamma Knife Radiosurgery on the neurosurgical management of skull-base lesions: The Combined Approach
Radiosurgery as part of the neurosurgical armamentarium: Educational Symposium November 24 th 2011 Impact of Gamma Knife Radiosurgery on the neurosurgical management of skull-base lesions: The Combined
More informationEuropean Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas
Page 1 of 47 Accepted Preprint first posted on 18 October 2017 as Manuscript EJE-17-0796 Page 1 sur 45 European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary
More informationBrain Tumors. Andrew J. Fabiano, MD FAANS. Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine
Brain Tumors Andrew J. Fabiano, MD FAANS Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine Brain Tumors Brain Tumor Basics Types of Tumors Cases Brain
More informationSBRT in early stage NSCLC
SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques
More informationProcess / Evidence Class. Clinical Assessment / III
Table 2: Endocrine Author Cozzi et al (2009) 1 Study Design: Prospectively followed case series. Fourteen patients had pre-op hypocortisolism. Patient Population: Seventy-two adult patients who underwent
More informationRadiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem
Radiotherapy and Brain Metastases Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem 24-02-2017 Possible strategies Watchful waiting Surgery Postop RT to resection cavity or WBRT postop SRS
More informationpanhypopituitarism Pattawan Wongwijitsook Maharat Nakhon Ratchasima hospital 17 Nov 2013
panhypopituitarism Pattawan Wongwijitsook Maharat Nakhon Ratchasima hospital 17 Nov 2013 PITUITARY GLAND (HYPOPHYSIS CEREBRI) The master of endocrine glands master of endocrine glands It is a small oval
More informationPituitary Tumors and Incidentalomas. Bijan Ahrari, MD, FACE, ECNU Palm Medical Group
Pituitary Tumors and Incidentalomas Bijan Ahrari, MD, FACE, ECNU Palm Medical Group Background Pituitary incidentaloma: a previously unsuspected pituitary lesion that is discovered on an imaging study
More informationRESEARCH ARTICLE. Abstract. Introduction. Materials and Methods
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.13.5279 Outcomes after Linac Based SRS/FSRT for Pituitary Adenomas RESEARCH ARTICLE Outcomes for Pituitary Adenoma Patients Treated with Linac- Based Stereotactic
More informationR J M E Romanian Journal of Morphology & Embryology
Rom J Morphol Embryol 2011, 52(3 Suppl):1041 1045 ORIGINAL PAPER R J M E Romanian Journal of Morphology & Embryology http://www.rjme.ro/ Conventional examination versus immunohistochemistry in the prediction
More informationCase Report A Rare Corticotroph-Secreting Tumor with Coexisting Prolactin and Growth Hormone Staining Cells
Case Reports in Endocrinology Volume 2012, Article ID 529730, 5 pages doi:10.1155/2012/529730 Case Report A Rare Corticotroph-Secreting Tumor with Coexisting Prolactin and Growth Hormone Staining Cells
More information(3) Pituitary tumours
Hypopituitarism Diabetes Insipidus Pituitary tumours (2) Dr T Kemp - Endocrinology and Metabolism Unit - Steve Biko Academic Hospital (3) Pituitary tumours Pituitary microadenoma - intrasellar adenoma
More informationTania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015
Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015 Most common brain tumor, affecting 8.5-15% of cancer patients. Treatment options: Whole brain radiation
More informationChapter 5 Section 3.1
Radiology Chapter 5 Section 3.1 Issue Date: March 27, 1991 Authority: 32 CFR 199.4(b)(2), (b)(2)(x), (c)(2)(viii), and (g)(15) 1.0 CPT 1 PROCEDURE CODES 37243, 61793, 61795, 77261-77421, 77427-77799, 0073T
More informationOutline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame
Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2013 Section:
More informationThe Molecular Pathology of Pituitary Tumors
Asa SL, Page 1 The Molecular Pathology of Pituitary Tumors Sylvia L. Asa, M.D., Ph.D. Department of Pathology, University Health Network and Toronto Medical Laboratories, Department of Laboratory Medicine
More informationGamma Knife Radiosurgery A tool for treating intracranial conditions. CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop
Gamma Knife Radiosurgery A tool for treating intracranial conditions CNSA Annual Congress 2016 Radiation Oncology Pre-congress Workshop ANGELA McBEAN Gamma Knife CNC State-wide Care Coordinator Gamma Knife
More information-Proton Beam Therapy in Paediatric Radiation Oncology -
-Proton Beam Therapy in Paediatric Radiation Oncology - Beate Timmermann, M.D. West German Proton Therapy Centre Essen Germany Preview Survival Toxicity Why protons? (theoretically) Experiences so far
More informationStereotactic radiotherapy
Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH
More informationThe Importance of Immunohistochemical Analysis in Silent Pituitary Adenoma. Intern at Siloam Hospital Lippo Village, Banten, Indonesia 2
Case Report The Importance of Immunohistochemical Analysis in Silent Pituitary Adenoma Ivan William Harsono 1, Nathania Victoria Stevina 1, Vivien Puspitasari 2, Julius July 3 1 Intern at Siloam Hospital
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM BRAIN METASTASES CNS Site Group Brain Metastases Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationPathology of pituitary gland. By: Shifaa Qa qa
Pathology of pituitary gland By: Shifaa Qa qa Sella turcica Adenohypophysis (80%): - epithelial cells - acidophil, basophil, chromophobe - Somatotrophs, Mammosomatotrophs, Corticotrophs, Thyrotrophs, Gonadotrophs
More informationOncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013
Oncological Management of Brain Tumours Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013 Outline General considerations of Primary Brain Tumours: epidemiology, pathology, presentation. Diagnosis
More informationBrain and Spine Tumors
Brain and Spine Tumors Andrew J. Fabiano, MD FAANS Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine Brain Tumors Brain Tumor Basics Types of Tumors Cases
More informationLong term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas
Pituitary (2010) 13:223 229 DOI 10.1007/s11102-010-0221-z Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas Edward F. Chang Michael E. Sughrue
More informationProlactin-Secreting Pituitary Adenomas (Prolactinomas) The Diagnostic Pathway (11-2K-234)
Prolactin-Secreting Pituitary Adenomas (Prolactinomas) The Diagnostic Pathway (11-2K-234) Common presenting symptoms/clinical assessment: Pituitary adenomas are benign neoplasms of the pituitary gland.
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationProton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations
Proton-Radiotherapy for Tumors of the Skull Base: Indications, Advantages, Limitations Eugen B. Hug, MD Director, Center for Proton-Radiotherapy, Paul Scherrer Institut, Villigen and Chair of Proton-Radiotherapy.
More informationFractionated Stereotactic Radiotherapy. Rationale, indications, & treatment techniques
Fractionated Stereotactic Radiotherapy Rationale, indications, & treatment techniques Radiobiological principles The BED (Gy) = D(1 + d/α/β) Assume BED 1 = BED 2 for tissue of an unknown α/β: Optic
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2015
More informationUCSF Uveal Melanoma Program: Outcomes with Proton Beam Radiation Therapy Kavita K. Mishra, M.D., M.P.H. UCSF Comprehensive Cancer Center
Disclosures UCSF Uveal Melanoma Program: Outcomes with Proton Beam Radiation Therapy No disclosures Kavita K. Mishra, M.D., M.P.H. UCSF Comprehensive Cancer Center UCSF Uveal Melanoma Program: Ocular Melanoma
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 04/01/2014 Section:
More informationTABLES. Table 1: Imaging. Congress of Neurological Surgeons Author (Year) Description of Study Classification Process / Evidence Class
TABLES Table 1: Imaging Kremer et al (2002) 2 Study Design: Prospective followed case series. Patient Population: Fifty adult patients with NFPA Study Description: Patients underwent MRI before surgery,
More informationPalliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased
Palliative radiotherapy near the end of life for brain metastases from lung cancer: a populationbased analysis Roel Schlijper Fellow Radiation Oncology BC Cancer, Prince George Disclosures No conflicts
More informationTherapeutic Objectives. Cushing s Disease Surgical Results. Cushing s Disease Surgical Results: Macroadenomas 10/24/2015
Therapeutic Objectives Update on the Management of Lewis S. Blevins, Jr., M.D. Correct the syndrome by lowering daily cortisol secretion to normal Eradicate any tumor that might threaten the health of
More informationPituitary Adenomas: Evaluation and Management. Fawn M. Wolf, MD 10/27/17
Pituitary Adenomas: Evaluation and Management Fawn M. Wolf, MD 10/27/17 Over 18,000 pituitaries examined at autopsy: -10.6% contained adenomas (1.5-27%) -Frequency similar for men and women and across
More informationGamma knife surgery in management of secretory pituitary adenoma Preliminary evaluation of role, efficacy and safety
International Journal of Clinical Medicine Research 2014; 1(2): 48-56 Published online June 10, 2014 (http://www.aascit.org/journal/ijcmr) Gamma knife surgery in management of secretory pituitary adenoma
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 11/20/2015
More informationRadiation Technology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, JAPAN
Analysis of Visual Loss Due to Radiation- Induced Optic Neuropathy After Particle Therapy for Head and Neck and Skull Base Tumors Adjacent to Optic Nerves Y. Demizu 1, M. Murakami 1, D. Miyawaki 1, Y.
More informationOutstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014
Outstanding Questions from Webinar: Long-Term Survival Outcomes for LGG Patients, May 5 th, 2014 Answers provided as a courtesy by Dana Farber Cancer Institute experts: Dr. Mark Kieran Dr. Peter Manley
More informationSpecial Procedures Rotation I/II SBRT, SRS, TBI, and TSET
University of Michigan Department of Radiation Oncology Division of Radiation Physics Special Procedures Rotation I/II SBRT, SRS, TBI, and TSET Resident: Rotation staff mentor/ advisor: _Scott Hadley,
More informationOptimal Management of Isolated HER2+ve Brain Metastases
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013 Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not
More informationLeksell Gamma Knife Icon. Treatment information
Leksell Gamma Knife Icon Treatment information You may be feeling frightened or overwhelmed by your recent diagnosis. It can be confusing trying to process a diagnosis, understand a new and challenging
More informationSTEREOTACTIC RADIATION THERAPY. Monique Blanchard ANUM Radiation Oncology Epworth HealthCare
STEREOTACTIC RADIATION THERAPY Monique Blanchard ANUM Radiation Oncology Epworth HealthCare Overview Stereotactic radiation therapy at Epworth Healthcare What is stereotactic radiation therapy? Delivery
More informationDosimetry, see MAGIC; Polymer gel dosimetry. Fiducial tracking, see CyberKnife radiosurgery
Subject Index Acoustic neuroma, neurofibromatosis type 2 complications 103, 105 hearing outcomes 103, 105 outcome measures 101 patient selection 105 study design 101 tumor control 101 105 treatment options
More informationRadiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management
Session 5: Symptoms management Radiotherapy symptoms control in bone mets Francesco Cellini GemelliART Ernesto Maranzano,MD Director of Oncology Department Chief of Radiation Oncology Centre S. Maria Hospital
More informationStereotactic Radiosurgery of World Health Organization Grade II and III Intracranial Meningiomas
Stereotactic Radiosurgery of World Health Organization Grade II and III Intracranial Meningiomas Treatment Results on the Basis of a 22-Year Experience Bruce E. Pollock, MD 1,2 ; Scott L. Stafford, MD
More informationSurgical therapeutic strategy for giant pituitary adenomas.
Biomedical Research 2017; 28 (19): 8284-8288 ISSN 0970-938X www.biomedres.info Surgical therapeutic strategy for giant pituitary adenomas. Han-Shun Deng, Zhi-Quan Ding, Sheng-fan Zhang, Zhi-Qiang Fa, Qing-Hua
More informationEnterprise Interest None
Enterprise Interest None Plurihormonal cells of normal anterior pituitary Lubov Mitrofanova¹, Petr Konovalov¹, Julia Krylova², Igor Kvetnoy² ¹Federal Almazov North-West Medical Research Centre, St. Petersburg,
More informationAcromegaly: Management of the Patient Who Has Failed Surgery
Acromegaly: Management of the Patient Who Has Failed Surgery Minnesota/Midwest Chapter of the American Association of Clinical Endocrinologists 8 th Annual Meeting October 14, 2017 Mark E. Molitch, M.D.
More informationTHE ANTERIOR PITUITARY. Embryology cont. Embryology of the pituitary BY MISPA ZUH HS09A179. Embryology cont. THE PITUIYARY GLAND Anatomy:
THE ANTERIOR PITUITARY BY MISPA ZUH HS09A179 Embryology of the pituitary The pituitary is formed early in embryonic life from the fusion of the Rathke s pouch (anterior) and the diencephalon ( posterior)
More informationThe Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence
Journal of Pathology and Translational Medicine 2016; 50: 419-425 ORIGINAL ARTICLE The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence Jee
More informationOtolaryngologist s Perspective of Stereotactic Radiosurgery
Otolaryngologist s Perspective of Stereotactic Radiosurgery Douglas E. Mattox, M.D. 25 th Alexandria International Combined ORL Conference April 18-20, 2007 Acoustic Neuroma Benign tumor of the schwann
More informationAlessandra Gorgulho, MD, MSc
Manejo do Meningioma que compromete o seio cavernoso: quando eu irradio Alessandra Gorgulho, MD, MSc Chefe Clínico-Científica Centro HCor de Neurociências Professora Visitante, Departamento de Neurocirurgia,
More informationEndocrinological Outcome Among Treated Craniopharyngioma Patients
Endocrinological Outcome Among Treated Craniopharyngioma Patients Afaf Al Sagheir, MD Head & Consultant, Section of Endocrinology/Diabetes Department of Pediatrics KFSH&RC Introduction Craniopharyngiomas
More information11 -Hydroxysteroid dehydrogenase, expression, corticotroph adenomas 68 70
Subject Index Activin activity decrease, gonadotroph 78 pituitary tumorigenesis, role 99 Adenoma, see also specific cell types angiogenesis, see Angiogenesis clonality, see Clonality, pituitary tumors
More informationPituitary adenomas and menopause
Pituitary adenomas and menopause Iulia Potorac Service d Endocrinologie Université de Liège CHU Liège RESULTATS Clinical case 1-38-year-old patient referred for exploration of premature ovarian failure
More informationMetastasis. 57 year old with progressive Headache and Right Sided Visual Loss
Metastasis 1% of sellar/parasellar masses Usually occurs with known primary Can involve third ventricle, hypothalamus, infundibular stalk May be both supra-, intrasellar 57 year old with progressive Headache
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: 6.01.10 Last Review: 11/2013 Origination: 1/1989 Next Review: 11/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationRadiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationClinical Commissioning Policy Proposition: Stereotactic radiosurgery/ radiotherapy for the treatment of pituitary adenomas [Adults]
Clinical Commissioning Policy Proposition: Stereotactic radiosurgery/ radiotherapy for the treatment of pituitary adenomas [Adults] Reference: NHS England 1603 First published: TBC Prepared by NHS England
More informationIntroduction to Endocrinology. Hypothalamic and Pituitary diseases Prolactinoma + Acromegaly
Introduction to Endocrinology. Hypothalamic and Pituitary diseases Prolactinoma + Acromegaly Dr. Peter Igaz MD PhD DSc 2nd Department of Medicine Semmelweis University Fields of Endocrinology Diseases
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationDisclosure SBRT. SBRT for Spinal Metastases 5/2/2010. No conflicts of interest. Overview
Stereotactic Body Radiotherapy (SBRT) for Recurrent Spine Tumors Arjun Sahgal M.D., F.R.C.P.C. Assistant Professor Princess Margaret Hospital Sunnybrook Health Sciences Center University of Toronto Department
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM MENINGIOMA CNS Site Group Meningioma Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION 3 2. PREVENTION
More informationStereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Policy Number: Original Effective Date: MM.05.008 05/12/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2017
More informationPituitary gland Pituitary fossa Mass: 5 gms DIMENSIONS 7mm (Ht) 9mm (AP) 11m(transverse) originates from Rathke s pouch and infundibulum
Pituitary gland Pituitary fossa Mass: 5 gms DIMENSIONS 7mm (Ht) 9mm (AP) 11m(transverse) originates from Rathke s pouch and infundibulum Cell type hormone Clinical syndrome Tumor type Somatotroph Growth
More informationClinical Commissioning Policy: Stereotactic radiosurgery/ radiotherapy for the treatment of pituitary adenomas (all ages)
Clinical Commissioning Policy: Stereotactic radiosurgery/ radiotherapy for the treatment of pituitary adenomas (all ages) NHS England Reference: 170044P 1 NHS England INFORMATION READER BOX Directorate
More informationSharon maslovitz Lis Maternity Hospital
Sharon maslovitz Lis Maternity Hospital Case report Chief complaint 27 yo, with PMC @ 31+3w, BCBA twins Complaints of severe rt parietal and retrobulbar headaches Medical background Healthy until 24yo
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM LOW GRADE GLIOMAS CNS Site Group Low Grade Gliomas Author: Dr. Norm Laperriere 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING
More informationMy approach to pathology of the pituitary gland
My approach to pathology of the pituitary gland N Y Y Al-Brahim and S L Asa J. Clin. Pathol. 2006;59;1245-1253 doi:10.1136/jcp.2005.031187 Updated information and services can be found at: http://jcp.bmj.com/cgi/content/full/59/12/1245
More informationLong-term results of gamma knife surgery for growth hormone producing pituitary adenoma: is the disease difficult to cure?
J Neurosurg (Suppl) 102:119 123, 2005 Long-term results of gamma knife surgery for growth hormone producing pituitary adenoma: is the disease difficult to cure? TATSUYA KOBAYASHI, M.D., PH.D., YOSHIMASA
More informationPathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry
European Journal of Endocrinology (2007) 156 203 216 ISSN 0804-4643 CLINICAL STUDY Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry
More informationDisclosures. The Thin Red Line Between Neuropathology and Head & Neck Pathology. Introduction CASE 1. Current Issues Tihan
Disclosures I have nothing to disclose The Thin Red Line Between Neuropathology and Head & Neck Pathology Tarik Tihan, MD, PhD UCSF, Department of Pathology Neuropathology Division Introduction Three cases
More informationSilent ACTHoma: A subclinical presentation of Cushing s disease in a 79 year old male
575 Silent ACTHoma: A subclinical presentation of Cushing s disease in a 79 year old male Meenal Malviya 1, Navneet Kumar 1*, Naseer Ahmad 2 1 MD; Department of Internal Medicine, Providence Hospital &
More informationWhere Has My Vision Gone? Evaluation of Sellar Lesions. Caleb Stowell,, HMS III Gillian Lieberman, MD November 2008
Where Has My Vision Gone? Evaluation of Sellar Lesions Caleb Stowell,, HMS III Gillian Lieberman, MD November 2008 Objectives Present a case highlighting the clinical presentation and evaluation of a sellar
More informationLaboratory data from the 1970s first showed that malignant melanoma
2265 Survival by Radiation Therapy Oncology Group Recursive Partitioning Analysis Class and Treatment Modality in Patients with Brain Metastases from Malignant Melanoma A Retrospective Study Jeffrey C.
More informationJMSCR Vol 05 Issue 01 Page January 2017
MEN1, AIP, PRKAR1A and CDKN1B are familial pituitary syndromes found to be associated with four different genes. Pituitary gland is situated in hypophyseal fossa which is bounded supero-laterally by dural
More informationProton Stereotactic Radiotherapy: Clinical Overview. Brian Winey, Ph.D. Physicist, MGH Assistant Professor, HMS
Proton Stereotactic Radiotherapy: Clinical Overview Brian Winey, Ph.D. Physicist, MGH Assistant Professor, HMS Acknowledgements Radiation Oncologists and Physicists at various institutions (MGH, MDACC,
More informationSpecialised Services Policy: CP22. Stereotactic Radiosurgery
Specialised Services Policy: CP22 Document Author: Assistant Director of Planning Executive Lead: Director of Planning ad Performance Approved by: Management Group Issue Date: 01 July 2015 Review Date:
More informationPEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
More informationPediatr Blood Cancer 2014
Low grade Glioma! 40% of pediatric brain tumors Pathologically, anatomically, clinically and biologically heterogeneous Leptomeningeal metastases in 5% Frequently protracted clinical course Long-Term Outcome
More informationClinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma
ORIGINAL ARTICLE Brain Tumor Res Treat 2016;4(1):1-7 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.1.1 Clinical Concerns about Recurrence of Non-Functioning Pituitary Adenoma
More informationIs dosimetry of multiple mets radiosurgery vendor platform dependent? Y. Zhang
Is dosimetry of multiple mets radiosurgery vendor platform dependent? Y. Zhang Linac Based -TrueBeam -Trilogy CyberKnife GammaKnife 2 Objectives To provide an overview of the physics of GammaKnife, CyberKnife
More informationNeurosurgical Management of Brain Tumours. Nicholas Little Neurosurgeon RNSH
Neurosurgical Management of Brain Tumours Nicholas Little Neurosurgeon RNSH General Most common tumours are metastatic 10x more common than primary Incidence of primary neoplasms is 20 per 100000 per year
More informationInsights into Thymic Epithelial Tumors: Radiation Therapy
Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical
More informationHigh and Low GH: an update of diagnosis and management of GH disorders
High and Low GH: an update of diagnosis and management of GH disorders Georgia Chapter-AACE 2017 Laurence Katznelson, MD Professor of Medicine and Neurosurgery Associate Dean of Graduate Medical Education
More informationInnovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy. Sue S. Yom, M.D., Ph.D.
Innovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy Sue S. Yom, M.D., Ph.D. Disclosures Genentech: advisory, research support ImClone: research support Plexxikon: research support
More informationNeuro-oncology Update Andrew Kokkino, MD Medical Director, The Neurosciences Institute at Sacred Heart at Riverbend May 20, 2013
Neuro-oncology Update 2013 Andrew Kokkino, MD Medical Director, The Neurosciences Institute at Sacred Heart at Riverbend May 20, 2013 Case 1 58 year old man with recent facial droop and HA s Thin, cachectic
More information